Rigel Pharmaceuticals Inc (RIGL) — Cash Flow-to-Debt Ratio
Rigel Pharmaceuticals Inc (RIGL) has a Cash Flow-to-Debt Ratio of 0.32x as of June 2026, meaning its operating cash flow of $30.65 Million could theoretically repay 0% of its total liabilities ($95.42 Million) in one year. See Rigel Pharmaceuticals Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Rigel Pharmaceuticals Inc Cash Flow-to-Debt Ratio (1999–2025)
Historical debt coverage capacity for Rigel Pharmaceuticals Inc across 27 annual periods. For the full cash flow conversion analysis, see how efficiently does Rigel Pharmaceuticals Inc generate cash.
Annual Cash Flow-to-Debt Ratio for Rigel Pharmaceuticals Inc (1999–2025)
Year-by-year debt coverage analysis for Rigel Pharmaceuticals Inc. Check Rigel Pharmaceuticals Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.62x | $75.66 Million | $122.11 Million | ▲ +216.3% |
| 2024 | 0.20x | $31.47 Million | $160.69 Million | ▲ +597.5% |
| 2023 | -0.04x | $-5.74 Million | $145.87 Million | ▲ +92.1% |
| 2022 | -0.50x | $-73.76 Million | $147.90 Million | ▼ -1262.0% |
| 2021 | 0.04x | $5.88 Million | $136.95 Million | ▲ +106.3% |
| 2020 | -0.68x | $-52.19 Million | $76.35 Million | ▼ -54.4% |
| 2019 | -0.44x | $-41.51 Million | $93.75 Million | ▲ +78.0% |
| 2018 | -2.01x | $-58.83 Million | $29.23 Million | ▲ +52.1% |
| 2017 | -4.20x | $-77.56 Million | $18.46 Million | ▼ -27.9% |
| 2016 | -3.28x | $-75.89 Million | $23.11 Million | ▼ -466.2% |
| 2015 | -0.58x | $-23.41 Million | $40.37 Million | ▲ +78.5% |
| 2014 | -2.69x | $-69.75 Million | $25.89 Million | ▲ +44.3% |
| 2013 | -4.83x | $-86.06 Million | $17.81 Million | ▼ -18.8% |
| 2012 | -4.07x | $-85.19 Million | $20.95 Million | ▼ -22.9% |
| 2011 | -3.31x | $-69.38 Million | $20.96 Million | ▼ -245.6% |
| 2010 | 2.27x | $46.74 Million | $20.56 Million | ▲ +168.3% |
| 2009 | -3.33x | $-102.78 Million | $30.88 Million | ▼ -27.6% |
| 2008 | -2.61x | $-103.52 Million | $39.69 Million | ▼ -67.9% |
| 2007 | -1.55x | $-52.21 Million | $33.61 Million | ▼ -12.8% |
| 2006 | -1.38x | $-35.84 Million | $26.01 Million | ▼ -53.1% |
| 2005 | -0.90x | $-35.17 Million | $39.08 Million | ▲ +37.4% |
| 2004 | -1.44x | $-38.15 Million | $26.52 Million | ▲ +31.0% |
| 2003 | -2.09x | $-32.44 Million | $15.55 Million | ▼ -14.2% |
| 2002 | -1.83x | $-34.53 Million | $18.90 Million | ▼ -100.1% |
| 2001 | -0.91x | $-15.98 Million | $17.51 Million | ▼ -20.1% |
| 2000 | -0.76x | $-11.59 Million | $15.25 Million | ▼ -59.2% |
| 1999 | -0.48x | $-7.83 Million | $16.41 Million | — |